Gene test could Fine-Tune transplant drug dosing
NCT ID NCT00552201
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether adjusting the first dose of the immunosuppressant drug tacrolimus based on a patient's CYP3A5 gene helps reach the right blood levels faster after kidney transplant. 280 kidney transplant recipients were randomly assigned to receive either a standard dose or a dose tailored to their genetic profile. The goal was to see if more patients in the gene-guided group achieved target tacrolimus levels within the first week.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tacrolimus
What this could lead to
If successful, this approach could help doctors personalize tacrolimus dosing for kidney transplant patients, potentially reducing the risk of rejection or side effects.
What could go wrong
This is a completed Phase 4 study with 280 participants, so results are available. However, the benefit may be limited to certain genetic groups, and the approach may not improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Angers
Angers, France
-
CHU Gabriel Montpied
Clermont-Ferrand, 63003, France
-
CHU Limoges - Hôpital Dupuytren
Limoges, 87042, France
-
CHU Poitiers- hôpital Jean Bernard
Poitiers, 86021, France
-
CHU Reims - Hôpital Maison Blanche
Reims, 51092, France
-
CHU Rennes - Hôpital Pontchaillou
Rennes, 35033, France
-
CHU Rouen - Hôpital de Bois-Guillaume
Bois-Guillaume, 76230, France
-
CHU Strasbourg - Hospices Civils
Strasbourg, 67091, France
-
CHU Tours - Hôpital Bretonneau
Tours, 37044, France
-
CHU de la côté de Nacre
Caen, 14033, France